Trial Profile
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Immune Globulin (Human), 10% Caprylate/ Chromatography Purified (lGIV -C) as a Corticosteroid Sparing Agent in Corticosteroid Dependent Patients with Generalized Myasthenia Gravis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Oct 2022
Price :
$35
*
At a glance
- Drugs Immune globulin (Primary)
- Indications Myasthenia gravis
- Focus Therapeutic Use
- Sponsors Grifols
- 12 Oct 2022 Primary endpoint (Percent of subjects achieving a 50% or greater reduction in corticosteroid dose) has not been met, according to Results published in the Neurology.
- 12 Oct 2022 Results published in the Neurology
- 01 Apr 2019 Status changed from active, no longer recruiting to completed.